Mutational heterogeneity in cancer and the search for new cancer-associated genes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reproducibility of scientific findings has been called into question.”
From Evaluating replicability of laboratory experiments in economics (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Melanoma has one of the highest rates of mutation of any cancer16.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells are genetically unstable, which contributes to their uncontrolled proliferation and the expression of antigens that can be recognized by the immune system.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…(GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8 ; MUC4 in melanoma 13 ; olfactory receptor OR2L13 in GBM 14 ; and TTN in breast cancer 12 and other tumor types 15 .”
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“…genes have already cropped up in recently published cancer genome studies, for example: LRP1B in glioblastoma (GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8…”
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504 · cited 2×
“Recent studies have also implicated HPV in head-and-neck cancers 5 .”
InfluentialSelf-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · cited 3×
“Recent work 19,20 has shown that the TpC mutations tend to occur in proximity to one another, consistent with the activity of APOBEC enzymes in damaged long single-strand DNA regions.”
Influential
Cited by
Items 801–900 of 1,039
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
van Dijk, N., Funt, S. A., Blank, C. U., Powles, T. B., Rosenberg, J. E., & van der Heijden, M. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.022 · Cited by 125
Chen, Y., Lu, Z., Qi, C., Yu, C., Li, Y., Wang, H., Wang, R., Luo, W., Shen, D., Ding, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01549-1 · Cited by 131
Precancerous neoplastic cells can move through the pancreatic ductal system
Makohon-Moore, A. P., Matsukuma, K., Zhang, M., Reiter, J. G., Gerold, J. M., Jiao, Y., Sikkema, L., Attiyeh, M. A., Yachida, S., Sandone, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0481-8 · Cited by 120
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
Colli, L. M., Machiela, M. J., Zhang, H., Myers, T. A., Jessop, L., Delattre, O., Yu, K. F., & Chanock, S. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3338 · Cited by 128
Bayesian inference of negative and positive selection in human cancers
Weghorn, D., & Sunyaev, S. R. (2017) · Nature Genetics · doi:10.1038/ng.3987 · Cited by 136
Self-citationAnalysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Zhou, R., Shi, C., Tao, W., Li, J., Wu, J., Han, Y., Yang, G., Gu, Z., Xu, S., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3442 · Cited by 135
Dalin, M. G., Katabi, N., Persson, M., Lee, K.-W., Makarov, V., Desrichard, A., Walsh, L. A., West, L., Nadeem, Z., Ramaswami, D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01178-z · Cited by 122
A Simple Model-Based Approach to Inferring and Visualizing Cancer Mutation Signatures
Shiraishi, Y., Tremmel, G., Miyano, S., & Stephens, M. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005657 · Cited by 120
Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers
McCreery, M. Q., Halliwill, K. D., Chin, D., Delrosario, R., Hirst, G., Vuong, P., Jen, K.-Y., Hewinson, J., Adams, D. J., & Balmain, A. (2015) · Nature Medicine · doi:10.1038/nm.3979 · Cited by 120
Lundberg, P., Takizawa, H., Kubovcakova, L., Guo, G., Hao-Shen, H., Dirnhofer, S., Orkin, S. H., Manz, M. G., & Skoda, R. C. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131371 · Cited by 106
Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes
Kooi, I. E., Mol, B. M., Massink, M. P. G., Ameziane, N., Meijers-Heijboer, H. E. J., Dommering, C. J., van Mil, S. E., de Vries, Y., van der Hout, A. H., Kaspers, G. J. L., et al. (2016) · Scientific Reports · doi:10.1038/srep25264 · Cited by 125
Deng, J., Chen, H., Zhou, D., Zhang, J., Chen, Y., Liu, Q., Ai, D., Zhu, H., Chu, L., Ren, W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01730-x · Cited by 120
Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features
Li, X., Xu, W., Kang, W., Wong, S. H., Wang, M., Zhou, Y., Fang, X., Zhang, X., Yang, H., Wong, C. H., et al. (2018) · Theranostics · doi:10.7150/thno.22010 · Cited by 128
The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet, F., Attalla, K., & Sfakianos, J. P. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.02.017 · Cited by 133
Puente, X. S., Jares, P., & Campo, E. (2018) · Blood · doi:10.1182/blood-2017-10-764373 · Cited by 125
Yang, S. Y. C., Lien, S. C., Wang, B. X., Clouthier, D., Hanna, Y., Cirlan, I., Zhu, K., Bruce, J. P., Ghamrasni, S. E., Iafolla, M. A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25432-7 · Cited by 126
Self-citationDreßler, L., Bortolomeazzi, M., Keddar, M. R., Mišetić, H., Sartini, G., Acha‐Sagredo, A., Montorsi, L., Wijewardhane, N., Repana, D., Nulsen, J., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02607-z · Cited by 131
Chromatin remodellers as therapeutic targets
Malone, H. A., & Roberts, C. W. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00978-5 · Cited by 127
Self-citationThe Case for Proteomics and Phospho‐Proteomics in Personalized Cancer Medicine
Doll, S., Gnad, F., & Mann, M. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800113 · Cited by 117
Mutation-Derived Neoantigens for Cancer Immunotherapy
Castle, J. C., Uduman, M., Pabla, S. S., Stein, R. B., & Buell, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01856 · Cited by 129
Wooten, D. J., Groves, S. M., Tyson, D. R., Liu, Q., Lim, J. S., Albert, R., Lopez, C. F., Sage, J., & Quaranta, V. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007343 · Cited by 130
Wang, G., Xu, D., Zhang, Z., Li, X., Shi, J., Sun, J., Li, X., Li, X., Zhou, M., & Zheng, T. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00200-4 · Cited by 131
Computational analysis of cancer genome sequencing data
Cortés‐Ciriano, I., Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., & Park, P. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00431-y · Cited by 134
“Currently, more sophisticated methods, such as MutSig2CV 88 and dNdScv 14 , utilize statistical models that consider several variables that correlate with mutation frequency, including transcriptional activity, the timing of DNA replication 88 , epigenetic context (that is, open versus closed…”
BackgroundMethodGrabbe, S., Haas, H., Diken, M., Kranz, L. M., Langguth, P., & Sahin, U. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0275 · Cited by 110
Research methods to change clinical practice for patients with rare cancers
Billingham, L. J., Malottki, K., & Steven, N. M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00396-4 · Cited by 128
Liu, W., Ruan, M., Wang, Y., Song, R., Ji, X., Xu, J., Dai, J., & Xue, W. (2018) · Small · doi:10.1002/smll.201801754 · Cited by 118
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
Mattos‐Arruda, L. D., Sammut, S., Ross, E. M., Bashford-Rogers, R. J. M., Greenstein, E., Markus, H., Morganella, S., Teng, Y. H. F., Maruvka, Y. E., Pereira, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.098 · Cited by 119
Self-citationYang, Y., Zhang, J., Chen, Y., Xu, R., Zhao, Q., & Guo, W. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.155 · Cited by 141
Cazier, J., Rao, S. R., McLean, C. M., Walker, A. K., Wright, B. J., Jaeger, E., Kartsonaki, C., Marsden, L., Yau, C., Camps, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4756 · Cited by 123
Chae, Y. K., Pan, A. P., Davis, A. A., Raparia, K., Mohindra, N. A., Matsangou, M., & Giles, F. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.011 · Cited by 126
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma
Cammareri, P., Rose, A., Vincent, D. F., Wang, J., Nagano, A., Libertini, S., Ridgway, R. A., Athineos, D., Coates, P. J., McHugh, A. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12493 · Cited by 126
Wanted DEAD/H or Alive: Helicases Winding Up in Cancers
Cai, W., Chen, Z. X., Rane, G., Singh, S. S., Choo, Z., Wang, C., Yuan, Y., Tan, T. Z., Arfuso, F., Yap, C. T., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw278 · Cited by 119
An expanded landscape of human long noncoding RNA
Jiang, S., Cheng, S., Ren, L., Wang, Q., Kang, Y.-J., Ding, Y., Hou, M. L., Yang, X., Lin, Y., Liang, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz621 · Cited by 123
Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure
Akdemir, K. C., Le, V. T., Kim, J. M., Killcoyne, S., King, D. A., Lin, Y., Tian, Y., Inoue, A., Amin, S. B., Robinson, F. S., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0708-0 · Cited by 124
Self-citationThe translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 124
Chen, T.-W., Lee, C.-C., Liu, H., Wu, C.-S., Pickering, C. R., Huang, P.-J., Wang, J., Chang, I. Y.-F., Yeh, Y.-M., Chen, C.-D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00493-9 · Cited by 115
Self-citationGenetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Merchant, M. S., Bernstein, D., Amoako, M., Baird, K., Fleisher, T. A., Morre, M., Steinberg, S. M., Sabatino, M., Stroncek, D. F., Venkatasan, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2550 · Cited by 112
Bloch, O. G., Lim, M. K., Sughrue, M. E., Komotar, R. J., Abrahams, J. M., O’Rourke, D. M., D’Ambrosio, A. L., Bruce, J. N., & Parsa, A. T. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1369 · Cited by 115
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 116
Wang, C., Yin, R., Dai, J., Gu, Y., Cui, S., Ma, H., Zhang, Z., Huang, J., Qin, N., Jiang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04492-2 · Cited by 116
Cai, H., Jing, C., Chang, X., Ding, D., Han, T., Yang, J., Lu, Z., Hu, X., Liu, Z., Wang, J., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1941-0 · Cited by 119
Xiong, X., Zhao, J., Pan, J., Liu, C., Guo, X., & Zhou, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03004 · Cited by 119
Integrated proteogenomic characterization of urothelial carcinoma of the bladder
Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01291-7 · Cited by 109
The effects of mutational processes and selection on driver mutations across cancer types
Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Böckler, B., & Graham, T. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04208-6 · Cited by 115
Alonso‐Curbelo, D., Riveiro‐Falkenbach, E., Pérez‐Guijarro, E., Cifdaloz, M., Karras, P., Osterloh, L., Megías, D., Cañón, E., Calvo, T. G., Olmeda, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.030 · Cited by 121
“This is remarkably daunting in cutaneous melanoma, where over 85,000 coding mutations have been reported (Lawrence et al., 2013).”
BackgroundIdentification and characterization of HPV-independent cervical cancers
Banister, C. E., Liu, C., Pirisi, L. A., Creek, K. E., & Buckhaults, P. (2017) · Oncotarget · doi:10.18632/oncotarget.14533 · Cited by 118
Hoefflin, R., Geißler, A.-L., Fritsch, R., Claus, R., Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D. H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00105 · Cited by 124
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
Tumor Heterogeneity Confounds and Illuminates: Assessing the implications
Kleppe, M., & Levine, R. L. (2014) · Nature Medicine · doi:10.1038/nm.3522 · Cited by 123
Omberg, L., Ellrott, K., Yuan, Y., Kandoth, C., Wong, C., Kellen, M. R., Friend, S. H., Stuart, J., Liang, H., & Margolin, A. A. (2013) · Nature Genetics · doi:10.1038/ng.2761 · Cited by 112
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 121
Breath analysis of cancer in the present and the future
Amor, R. E., Nakhleh, M. K., Barash, O., & Haick, H. (2019) · European Respiratory Review · doi:10.1183/16000617.0002-2019 · Cited by 123
Marzio, A., Kurz, E., Sahni, J. M., Di Feo, G., Puccini, J., Jiang, S., Hirsch, C. A., Arbini, A. A., Wu, W. L., Pass, H. I., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.005 · Cited by 110
Robustness of Next Generation Sequencing on Older Formalin-Fixed Paraffin-Embedded Tissue
Carrick, D. M., Mehaffey, M. G., Sachs, M. C., Altekruse, S. F., Camalier, C. E., Chuaqui, R. F., Cozen, W., Das, B., Hernandez, B. Y., Lih, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127353 · Cited by 112
Self-citationKarlsson, A., Jönsson, M., Lauss, M., Brunnström, H., Jönsson, P., Borg, Å., Jönsson, G. B., Ringnér, M., Planck, M., & Staaf, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1087 · Cited by 120
Zheng, C. L., Wang, N. J., Chung, J., Moslehi, H., Sanborn, J. Z., Hur, J. S., Collisson, E. A., Vemula, S. S., Naujokas, A., Chiotti, K. E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.031 · Cited by 107
“Somatic point mutations and chromosomal aberrations in cancer are not distributed uniformly throughout the genome (Alexan-drov et al., 2013; Ja¨ger et al., 2013; Lawrence et al., 2013; Polak et al., 2014).”
BackgroundResultInfluentialPriest, J. R., Osoegawa, K., Mohammed, N., Nanda, V., Kundu, R., Schultz, K., Lammer, E. J., Girirajan, S., Scheetz, T., Waggott, D., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005963 · Cited by 113
The challenges of tumor genetic diversity
Mroz, E. A., & Rocco, J. W. (2016) · Cancer · doi:10.1002/cncr.30430 · Cited by 121
The molecular basis of breast cancer pathological phenotypes
Heng, Y. J., Lester, S. C., Tse, G. M.-K., Factor, R. E., Allison, K. H., Collins, L. C., Chen, Y., Jensen, K. C., Johnson, N. B., Jeong, J. C., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4847 · Cited by 122
Induction of neoantigen-reactive T cells from healthy donors
Ali, M., Földvári, Z., Giannakopoulou, E., Böschen, M.-L., Strønen, E., Yang, W., Toebes, M., Schubert, B., Kohlbacher, O., Schumacher, T. N., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0170-6 · Cited by 119
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H., Dietlein, F., He, M. X., Margolis, C. A., Elmarakeby, H. A., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 114
Pathway and network analysis of more than 2500 whole cancer genomes
Reyna, M. A., Haan, D., Paczkowska, M., Verbeke, L. P. C., Vazquez, M., Kahraman, A., Pulido-Tamayo, S., Barenboim, J., Wadi, L., Dhingra, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14367-0 · Cited by 112
Self-citationThe genomic landscape of Mongolian hepatocellular carcinoma
Candia, J., Bayarsaikhan, E., Tandon, M., Budhu, A., Forgues, M., Товуу, Л.-О., Tudev, U., Lack, J., Chao, A., Chinburen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18186-1 · Cited by 123
Structural variations in cancer and the 3D genome
Dubois, F. P. B., Sidiropoulos, N., Weischenfeldt, J., & Beroukhim, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00488-9 · Cited by 129
“It is also possible that the alteration occurs frequently during cell division, including in cells that do not become cancer 5,60,61 .”
BackgroundCancer whole-genome sequencing: present and future
Nakagawa, H., Wardell, C. P., Furuta, M., Taniguchi, H., & Fujimoto, A. (2015) · Oncogene · doi:10.1038/onc.2015.90 · Cited by 123
Allison, K. H., & Sledge, G. W. (2014) · PubMed · Cited by 144
Choi, M., Kadara, H. N., Zhang, J., Parra, E. R., Rodriguez‐Canales, J., Gaffney, S. G., Zhao, Z.-M., Behrens, C., Fujimoto, J., Chow, C.-W. B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw437 · Cited by 111
Pereira, C., Gimenez-Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gomez, A., Navarro, A., Condom, E., Moran, S., Gomez-Lopez, G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 109
Integrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers
Zhu, B., Song, N., Shen, R., Arora, A., Machiela, M. J., Song, L., Landi, M. T., Ghosh, D., Chatterjee, N., Baladandayuthapani, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17031-8 · Cited by 109
Li, X., Wang, M., Yang, M., Dai, H., Zhang, B., Wang, W., Chu, X. L., Wang, X., Zheng, H., Niu, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy011 · Cited by 124
Yang, S. Y. C., Lheureux, S., Karakasis, K., Burnier, J. V., Bruce, J. P., Clouthier, D., Danesh, A., Quevedo, R., Dowar, M., Hanna, Y., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0590-x · Cited by 122
Self-citationAtezolizumab for the treatment of triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552255 · Cited by 117
Lin, Z., Huang, L., Li, S., Gu, J., Cui, X., & Zhou, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-78560-3 · Cited by 120
Mutational landscape of gray zone lymphoma
Sarkozy, C., Hung, S. S., Chavez, E. A., Duns, G., Takata, K., Chong, L. C., Aoki, T., Jiang, A., Miyata‐Takata, T., Telenius, A., et al. (2020) · Blood · doi:10.1182/blood.2020007507 · Cited by 116
Lanzós, A., Carlevaro-Fita, J., Mularoni, L., Reverter, F., Palumbo, E., Guigó, R., & Johnson, R. (2017) · Scientific Reports · doi:10.1101/065805 · Cited by 128
Gutiérrez-Gil, B., Arranz, J. J., & Wiener, P. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00167 · Cited by 104
Gherardin, N. A., Loh, L., Admojo, L., Davenport, A. J., Richardson, K., Rogers, A. J., Darcy, P. K., Jenkins, M. R., Prince, H. M., Harrison, S. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22130-1 · Cited by 111
S100 family proteins in inflammation and beyond
Sreejit, G., Flynn, M., Patil, M., Krishnamurthy, P., Murphy, A. J., & Nagareddy, P. R. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.02.006 · Cited by 122
Huang, K. K., Ma, H., Chong, R. H. H., Uchihara, T., Lian, B. S. X., Zhu, F., Sheng, T., Srivastava, S., Tay, S. T., Sundar, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.004 · Cited by 122
Graph Neural Networks in Modern AI-Aided Drug Discovery
Zhang, O., Lin, H., Zhang, X., Wang, X., Wu, Z., Ye, Q., Zhao, W., Wang, J., Ying, K., Kang, Y., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00461 · Cited by 141
Brauner, E., Gunda, V., Borre, P. V., Zurakowski, D., Kim, Y. S., Dennett, K. V., Amin, S., Freeman, G. J., & Parangi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7839 · Cited by 111
Focus on cutaneous and uveal melanoma specificities
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 122
Titin Mutation in Familial Restrictive Cardiomyopathy
Peled, Y., Gramlich, M., Yoskovitz, G., Feinberg, M. S., Afek, A. B., Polak‐Charcon, S., Pras, E., Sela, B., Konen, E., Weissbrod, O., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.037 · Cited by 109
Wu, K., Zhang, X., Li, F., Xiao, D., Hou, Y., Zhu, S., Liu, D., Ye, X., Ye, M., Yang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms10131 · Cited by 115
Hitting the Target: How T Cells Detect and Eliminate Tumors
Zamora, A. E., Crawford, J. C., & Thomas, P. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701413 · Cited by 124
Bladder Cancer: New Insights into Its Molecular Pathology
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10040100 · Cited by 121
Xiong, K., Zhang, Y., Wen, Q., Luo, J., Lü, Y., Wu, Z., Wang, B., Chen, Y., Zhao, L., & Fu, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119875 · Cited by 109
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Tothill, R. W., Li, J., Mileshkin, L., Doig, K., Siganakis, T., Cowin, P. A., FELLOWES, A. P., Semple, T. J., Fox, S. B., Byron, K. A., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4251 · Cited by 113
Systematic analysis of somatic mutations impacting gene expression in 12 tumour types
Ding, J., McConechy, M. K., Horlings, H. M., Ha, G., Chan, F. C., Funnell, T., Mullaly, S. C., Reimand, J., Bashashati, A., Bader, G. D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9554 · Cited by 117
Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome
Woollard, W. J., Pullabhatla, V., Lorenc, A., Patel, V. M., Butler, R. M., Bayega, A., Begum, N., Bakr, F. S., Dedhia, K., Fisher, J. N. B., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699843 · Cited by 115
Self-citationAnti-colon-cancer effects of polysaccharides: A mini-review of the mechanisms
Ji, X., Peng, Q., & Wang, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.03.186 · Cited by 110
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
Song, D., Powles, T. B., Shi, L., Zhang, L., Ingersoll, M. A., & Lu, Y. (2019) · The Journal of Pathology · doi:10.1002/path.5306 · Cited by 116
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Wienand, K., Kamburov, A., Griffin, G. K., Chen, P.-H., Lako, A., Redd, R. A., et al. (2019) · Blood · doi:10.1182/blood.2019002067 · Cited by 109
Self-citationPaul, M. R., Pan, T.-C., Pant, D. K., Shih, N. N. C., Chen, Y., Harvey, K. L., Solomon, A. C., Lieberman, D. B., Morrissette, J. J. D., Soucier-Ernst, D., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129941 · Cited by 125
“MutSigCV2 (19) was used to determine SMGs based on coding mutations and per-sample background mutation rates.”
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 116
Bernstein, N., Spencer Chapman, M., Nyamondo, K., Chen, Z., Williams, N., Mitchell, E., Campbell, P. J., Cohen, R. L., & Nangalia, J. (2024) · Nature Genetics · doi:10.1038/s41588-024-01755-1 · Cited by 115
“…0.04, maxsecond-tumor 0.05, foxog 0.9, snvcluster50 2, snvcluster100 4, repeats 12), (4) indels with 10 or fewer reads supporting the alternate allele 17 , and (5) variants in the gene MUC , olfactory genes and genes with recurrent synonymous mutations due to high rates of false positivity 63,64 .”
InfluentialAPOBEC3 genes: retroviral restriction factors to cancer drivers
Henderson, S. R., & Fenton, T. R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.007 · Cited by 120
A Cancer Theory Kerfuffle Can Lead to New Lines of Research
Baker, S. G. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju405 · Cited by 116
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D.-A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- National Institutes of Health (US)
- Harvard University (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Lawrence, Michael S.
- Polak, Paz
- Kryukov, Gregory V.
- Cibulskis, Kristian
- Sivachenko, Andrey
- Carter, Scott L.
- Stewart, Chip
- Mermel, Craig H.
- Roberts, Steven A.
- Hammerman, Peter S.
- McKenna, Aaron
- Drier, Yotam
- Zou, Lihua
- Pugh, Trevor J.
- Stransky, Nicolas
- Helman, Elena
- Kim, Jaegil
- Auclair, Daniel
- Saksena, Gordon
- Noble, Michael
- Lin, Pei
- Heiman, David I.
- Imielinski, Marcin
- Hernandez, Bryan
- Hodis, Eran
- Baca, Sylvan
- Dulak, Austin M.
- Lohr, Jens
- Landau, Dan-Avi
- Wu, Catherine J.
- Koren, Amnon
- McCarroll, Steven A.
- Mora, Jaume
- Crompton, Brian
- Winckler, Wendy
- Ardlie, Kristin
- Gabriel, Stacey B.
- Roberts, Charles W. M.
- Biegel, Jaclyn A.
- Stegmaier, Kimberly
- Bass, Adam J.
- Garraway, Levi A.
- Meyerson, Matthew
- Golub, Todd R.
- Gordenin, Dmitry A.
- Sunyaev, Shamil
- Lander, Eric S.
- Getz, Gad
- Venue
- Nature
- Published
- 2013-06-16
- Volume
- 499
- Issue
- 7457
- Pages
- 214-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3919509
- OpenAlex
- W2009720434
- Cited by
- 5,461
- References
- 30
- Citations by year
- 2026: 147 · 2025: 230 · 2024: 288 · 2023: 361 · 2022: 468 · 2021: 580 · 2020: 582 · 2019: 507 · 2018: 537 · 2017: 529 · 2016: 485 · 2015: 396 · 2014: 280 · 2013: 64
- FWCI
- 143.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U24CA143845, T32CA009216, T32CA009172)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Environmental Health Sciences (Z01ES065073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- mutational heterogeneity, cancer genes, MutSigCV, driver mutations, mutation frequency, lung cancer, lung squamous cell carcinoma, DNA replication timing, transcriptional activity
- MeSH terms
- False Positive Reactions, Humans, Lung Neoplasms, Mutation, Neoplasms, Oncogenes, Reproducibility of Results, Gene Expression, Genome, Human, Artifacts, Neoplasms, Squamous Cell, Sample Size, Genetic Heterogeneity, DNA Replication Timing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.